Literature DB >> 20518719

Surface plasmon resonance for vaccine design and efficacy studies: recent applications and future trends.

Stephen Hearty1, Paul J Conroy, B Vijayalakshmi Ayyar, Barry Byrne, Richard O'Kennedy.   

Abstract

The lack of a clear correlation between design and protection continues to present a barrier to progress in vaccine research. In this article, we outline how surface plasmon resonance (SPR) biosensors are emerging as tools to help resolve some of the key biophysical determinants of protection and, thereby, facilitate more rational vaccine design campaigns. SPR technology has contributed significantly to our understanding of the complex biophysical determinants of HIV neutralization and offers a platform for preclinical evaluation of vaccine candidates. In particular, the concept of reverse-engineering HIV vaccine targets based on known broadly neutralizing antibody modalities is explored and extended to include other infectious diseases, such as malaria and influenza, and other diseases such as cancer. The analytical capacity afforded by SPR includes serum screening to monitor immune responses and highly efficient quality-control surveillance measures. These are discussed alongside key technological advances, such as developments in sample throughput, and a perspective predicting continued growth and diversification of the role of SPR in vaccine development is proposed.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20518719     DOI: 10.1586/erv.10.52

Source DB:  PubMed          Journal:  Expert Rev Vaccines        ISSN: 1476-0584            Impact factor:   5.217


  16 in total

1.  Unraveling protein-protein interactions in clathrin assemblies via atomic force spectroscopy.

Authors:  Albert J Jin; Eileen M Lafer; Jennifer Q Peng; Paul D Smith; Ralph Nossal
Journal:  Methods       Date:  2012-12-25       Impact factor: 3.608

2.  Acquired antibodies to merozoite antigens in children from Uganda with uncomplicated or severe Plasmodium falciparum malaria.

Authors:  Hodan Ahmed Ismail; Ulf Ribacke; Linda Reiling; Johan Normark; Tom Egwang; Fred Kironde; James G Beeson; Mats Wahlgren; Kristina E M Persson
Journal:  Clin Vaccine Immunol       Date:  2013-06-05

3.  Methods to measure vaccine immunity.

Authors:  Vasso Apostolopoulos; Francesco M Marincola
Journal:  Expert Rev Vaccines       Date:  2010-06       Impact factor: 5.217

Review 4.  Role of plasmonics in detection of deadliest viruses: a review.

Authors:  Foozieh Sohrabi; Sajede Saeidifard; Masih Ghasemi; Tannaz Asadishad; Seyedeh Mehri Hamidi; Seyed Masoud Hosseini
Journal:  Eur Phys J Plus       Date:  2021-06-20       Impact factor: 3.911

Review 5.  How to assess the binding strength of antibodies elicited by vaccination against HIV and other viruses.

Authors:  P J Klasse
Journal:  Expert Rev Vaccines       Date:  2016-01-06       Impact factor: 5.217

6.  The membrane-proximal region (MPR) of herpes simplex virus gB regulates association of the fusion loops with lipid membranes.

Authors:  Spencer S Shelly; Tina M Cairns; J Charles Whitbeck; Huan Lou; Claude Krummenacher; Gary H Cohen; Roselyn J Eisenberg
Journal:  MBio       Date:  2012-11-20       Impact factor: 7.867

7.  High affinity antibodies to Plasmodium falciparum merozoite antigens are associated with protection from malaria.

Authors:  Sreenivasulu B Reddy; Robin F Anders; James G Beeson; Anna Färnert; Fred Kironde; Sharon Kühlman Berenzon; Mats Wahlgren; Sara Linse; Kristina E M Persson
Journal:  PLoS One       Date:  2012-02-21       Impact factor: 3.240

8.  Glycopeptide-based antibody detection in multiple sclerosis by surface plasmon resonance.

Authors:  Feliciana Real-Fernández; Irene Passalacqua; Elisa Peroni; Mario Chelli; Francesco Lolli; Anna Maria Papini; Paolo Rovero
Journal:  Sensors (Basel)       Date:  2012-05-02       Impact factor: 3.576

9.  How Should Antibodies against P. falciparum Merozoite Antigens Be Measured?

Authors:  Sriwipa Chuangchaiya; Kristina E M Persson
Journal:  J Trop Med       Date:  2013-04-18

10.  Roadmap to developing a recombinant coronavirus S protein receptor-binding domain vaccine for severe acute respiratory syndrome.

Authors:  Shibo Jiang; Maria Elena Bottazzi; Lanying Du; Sara Lustigman; Chien-Te Kent Tseng; Elena Curti; Kathryn Jones; Bin Zhan; Peter J Hotez
Journal:  Expert Rev Vaccines       Date:  2012-12       Impact factor: 5.217

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.